Testicular toxicity evaluation of two antimony compounds, antimony trioxide and antimony potassium tartrate, in rats and mice

Minoru Omura, Akiyo Tanaka, Miyuki Hirata, Naohide Inoue

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Testicular toxicities of antimony compounds were evaluated in rats and mice. The slightly water-soluble antimony compound antimony trioxide (ATO) and the highly water-soluble antimony compound antimony potassium tartrate (APT) were examined. Methods: Daily doses of the compounds were 27.4, 12.0 and 1,200 mg/kg body weight in the APT group, low-ATO group and high-ATO group, respectively. The corresponding daily doses of antimony were 10, 10 and 1,000 mg/kg body weight, in the APT group, low-ATO group and high-ATO group, respectively. Both compounds were administered by garage gavage: rats, 3 days per week for 4 weeks; mice, 5 days per week for 4 weeks. Results: Neither compound reduced the weights of reproductive organs or accessory sex organs nor affected sperm parameters. Few marked histopathologic changes were found in the testes of the treated animals. Even at 1,200 mg/kg body weight, which is greater than the LD50 of APT, ATO produced no effects. Conclusions: In this study, it was found that ATO and APT are not toxic to testes in rodents.

Original languageEnglish
Pages (from-to)15-18
Number of pages4
JournalEnvironmental health and preventive medicine
Volume7
Issue number1
DOIs
Publication statusPublished - Apr 22 2002

Fingerprint

Antimony Potassium Tartrate
Antimony
Body Weight
Testis
Genitalia
Organ Size
Water
Poisons
Lethal Dose 50
antimony trioxide
Spermatozoa
Rodentia

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

@article{2ba7c2ddd1e54ed6926b3131e378bb27,
title = "Testicular toxicity evaluation of two antimony compounds, antimony trioxide and antimony potassium tartrate, in rats and mice",
abstract = "Objectives: Testicular toxicities of antimony compounds were evaluated in rats and mice. The slightly water-soluble antimony compound antimony trioxide (ATO) and the highly water-soluble antimony compound antimony potassium tartrate (APT) were examined. Methods: Daily doses of the compounds were 27.4, 12.0 and 1,200 mg/kg body weight in the APT group, low-ATO group and high-ATO group, respectively. The corresponding daily doses of antimony were 10, 10 and 1,000 mg/kg body weight, in the APT group, low-ATO group and high-ATO group, respectively. Both compounds were administered by garage gavage: rats, 3 days per week for 4 weeks; mice, 5 days per week for 4 weeks. Results: Neither compound reduced the weights of reproductive organs or accessory sex organs nor affected sperm parameters. Few marked histopathologic changes were found in the testes of the treated animals. Even at 1,200 mg/kg body weight, which is greater than the LD50 of APT, ATO produced no effects. Conclusions: In this study, it was found that ATO and APT are not toxic to testes in rodents.",
author = "Minoru Omura and Akiyo Tanaka and Miyuki Hirata and Naohide Inoue",
year = "2002",
month = "4",
day = "22",
doi = "10.1265/ehpm.2002.15",
language = "English",
volume = "7",
pages = "15--18",
journal = "Environmental Health and Preventive Medicine",
issn = "1342-078X",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Testicular toxicity evaluation of two antimony compounds, antimony trioxide and antimony potassium tartrate, in rats and mice

AU - Omura, Minoru

AU - Tanaka, Akiyo

AU - Hirata, Miyuki

AU - Inoue, Naohide

PY - 2002/4/22

Y1 - 2002/4/22

N2 - Objectives: Testicular toxicities of antimony compounds were evaluated in rats and mice. The slightly water-soluble antimony compound antimony trioxide (ATO) and the highly water-soluble antimony compound antimony potassium tartrate (APT) were examined. Methods: Daily doses of the compounds were 27.4, 12.0 and 1,200 mg/kg body weight in the APT group, low-ATO group and high-ATO group, respectively. The corresponding daily doses of antimony were 10, 10 and 1,000 mg/kg body weight, in the APT group, low-ATO group and high-ATO group, respectively. Both compounds were administered by garage gavage: rats, 3 days per week for 4 weeks; mice, 5 days per week for 4 weeks. Results: Neither compound reduced the weights of reproductive organs or accessory sex organs nor affected sperm parameters. Few marked histopathologic changes were found in the testes of the treated animals. Even at 1,200 mg/kg body weight, which is greater than the LD50 of APT, ATO produced no effects. Conclusions: In this study, it was found that ATO and APT are not toxic to testes in rodents.

AB - Objectives: Testicular toxicities of antimony compounds were evaluated in rats and mice. The slightly water-soluble antimony compound antimony trioxide (ATO) and the highly water-soluble antimony compound antimony potassium tartrate (APT) were examined. Methods: Daily doses of the compounds were 27.4, 12.0 and 1,200 mg/kg body weight in the APT group, low-ATO group and high-ATO group, respectively. The corresponding daily doses of antimony were 10, 10 and 1,000 mg/kg body weight, in the APT group, low-ATO group and high-ATO group, respectively. Both compounds were administered by garage gavage: rats, 3 days per week for 4 weeks; mice, 5 days per week for 4 weeks. Results: Neither compound reduced the weights of reproductive organs or accessory sex organs nor affected sperm parameters. Few marked histopathologic changes were found in the testes of the treated animals. Even at 1,200 mg/kg body weight, which is greater than the LD50 of APT, ATO produced no effects. Conclusions: In this study, it was found that ATO and APT are not toxic to testes in rodents.

UR - http://www.scopus.com/inward/record.url?scp=0036220020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036220020&partnerID=8YFLogxK

U2 - 10.1265/ehpm.2002.15

DO - 10.1265/ehpm.2002.15

M3 - Article

VL - 7

SP - 15

EP - 18

JO - Environmental Health and Preventive Medicine

JF - Environmental Health and Preventive Medicine

SN - 1342-078X

IS - 1

ER -